---
title: "605177.SH (605177.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/605177.SH/news.md"
symbol: "605177.SH"
name: "605177.SH"
parent: "https://longbridge.com/en/quote/605177.SH.md"
datetime: "2026-05-21T03:35:09.328Z"
locales:
  - [en](https://longbridge.com/en/quote/605177.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/605177.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/605177.SH/news.md)
---

# 605177.SH (605177.SH) — Related News

### [EAST-ASIA PHARMACEUTICAL's subsidiary has obtained the raw material drug registration certificate for Fumaric Acid Vorinostat in South Korea](https://longbridge.com/en/news/285684906.md)
*2026-05-08T07:58:04.000Z*
> EAST-ASIA PHARMACEUTICAL's wholly-owned subsidiary Jiangxi Shanyuan Pharmaceutical Co., Ltd. has obtained the registrati

### [EAST-ASIA PHARMACEUTICAL: First quarter revenue increased by nearly 40% year-on-year, with a continued trend of recovering demand for cephalosporins](https://longbridge.com/en/news/284591231.md)
*2026-04-29T13:59:03.000Z*
> On April 29th, after the market closed, EAST-ASIA PHARMACEUTICAL disclosed its Q1 2026 report. During the reporting peri

### [](https://longbridge.com/en/news/284158551.md)
*2026-04-27T05:54:07.000Z*
> A-share pharmaceutical stocks showed volatile strength; Guangji Pharma hit the limit-up in the afternoon, while Fushine,

### [EAST-ASIA PHARMACEUTICAL: Fourth quarter revenue increased by 46.18% year-on-year, with breakthroughs in the integration of raw material drug formulations](https://longbridge.com/en/news/283663332.md)
*2026-04-22T12:13:37.000Z*
> On April 22nd, after the market closed, EAST-ASIA PHARMACEUTICAL (605177) disclosed its 2025 annual report. During the r

### [EAST-ASIA PHARMACEUTICAL released its 2025 annual performance, with a net loss attributable to the parent company of 82.39 million yuan](https://longbridge.com/en/news/283621516.md)
*2026-04-22T08:11:02.000Z*
> EAST-ASIA PHARMACEUTICAL released its 2025 annual report, with revenue of 940 million yuan, a year-on-year decrease of 2

### [EAST-ASIA PHARMACEUTICAL: Saxagliptin and Metformin Sustained-Release Tablets Obtained Drug Registration Certificate](https://longbridge.com/en/news/279220664.md)
*2026-03-16T07:44:03.000Z*
> EAST-ASIA PHARMACEUTICAL announced that the company has obtained the drug registration certificate for Saxagliptin and M

### [EAST-ASIA PHARMACEUTICAL: Fumaric Acid Vorinostat Tablets Obtain Drug Registration Certificate](https://longbridge.com/en/news/277744302.md)
*2026-03-04T08:05:05.000Z*
> EAST-ASIA PHARMACEUTICAL recently obtained the drug registration certificate for Vonoprazan Fumarate Tablets issued by t